Topical Ruxolitinib in Chronic Hand Dermatitis

Chronic Hand Dermatitis Clinical Trial

Official title:
Topical Ruxolitinib (Jak1/Jak2 Inhibitor) in Chronic Hand Dermatitis Attenuates Inflammation and Enhances Skin Barrier Repair

Status Active, not recruiting

Clinical Trial Summary

This is an investigator-initiated, proof of concept, open study to assess efficacy of a topical Ruxolitinib in subjects with Chronic Hand Dermatitis (CHD). The study will be conducted at the University of Rochester Medical center, Dermatology Department - Rochester, NY. Qualified and enrolled subjects (see Inclusion/Exclusion criteria) will be required to come to URMC Dermatology Clinic for at least five visits.

Clinical Trial Description

This is a single-center study anticipating to enroll 15 participants with chronic hand dermatitis. Eligible participants will receive Ruxolitinib to apply twice daily for 12 weeks. Participants will be required to be seen every 4 weeks until week 16. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05293717
Study type	Interventional
Source	University of Rochester
Contact
Status	Active, not recruiting
Phase	Phase 1/Phase 2
Start date	July 11, 2022
Completion date	December 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01482663` - Chronic Hand Eczema - Self-management and Prognosis	N/A
Completed	`NCT01545284` - Pilot Study on the Use of Acitretin for the Treatment of Severe Chronic Hand Dermatitis	Phase 2/Phase 3
Completed	`NCT00226707` - Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis	Phase 3
Completed	`NCT03728504` - Study to Evaluate ASN002 in Subjects With Moderate To Severe Chronic Hand Eczema	Phase 2
Withdrawn	`NCT03741933` - Apremilast and Moderate to Severe Chronic Hand Dermatitis	Phase 4
Completed	`NCT00556855` - Comparison Study With E-DO in Chronic Hand Dermatitis	N/A